Extending the Breast Cancer Surveillance Consortium Model of Invasive Breast Cancer

被引:2
|
作者
Gard, Charlotte C. [1 ]
Tice, Jeffrey A. [2 ]
Miglioretti, Diana L. [3 ,4 ]
Sprague, Brian L. [5 ,6 ]
Bissell, Michael C. S. [3 ]
Henderson, Louise M. [7 ]
Kerlikowske, Karla [8 ,9 ,10 ]
机构
[1] New Mexico State Univ, Dept Econ Appl Stat & Int Business, Las Cruces, NM USA
[2] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, 1545 Divisadero St,Ste 309, San Francisco 94143, CA USA
[3] Univ Calif Davis, Davis, CA USA
[4] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA USA
[5] Univ Vermont, Dept Surg, Canc Ctr, Burlington, VT USA
[6] Univ Vermont, Canc Ctr, Dept Radiol, Burlington, VT USA
[7] Univ N Carolina, Dept Radiol, Chapel Hill, NC USA
[8] Univ Calif San Francisco, Dept Vet Affairs, Gen Internal Med Sect, San Francisco, CA USA
[9] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[10] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA
关键词
RISK PREDICTION; FAMILY-HISTORY; WOMEN; DENSITY; PERFORMANCE; VALIDATION;
D O I
10.1200/JCO.22.02470
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSEWe extended the Breast Cancer Surveillance Consortium (BCSC) version 2 (v2) model of invasive breast cancer risk to include BMI, extended family history of breast cancer, and age at first live birth (version 3 [v3]) to better inform appropriate breast cancer prevention therapies and risk-based screening.METHODSWe used Cox proportional hazards regression to estimate the age- and race- and ethnicity-specific relative hazards for family history of breast cancer, breast density, history of benign breast biopsy, BMI, and age at first live birth for invasive breast cancer in the BCSC cohort. We evaluated calibration using the ratio of expected-to-observed (E/O) invasive breast cancers in the cohort and discrimination using the area under the receiver operating characteristic curve (AUROC).RESULTSWe analyzed data from 1,455,493 women age 35-79 years without a history of breast cancer. During a mean follow-up of 7.3 years, 30,266 women were diagnosed with invasive breast cancer. The BCSC v3 model had an E/O of 1.03 (95% CI, 1.01 to 1.04) and an AUROC of 0.646 for 5-year risk. Compared with the v2 model, discrimination of the v3 model improved most in Asian, White, and Black women. Among women with a BMI of 30.0-34.9 kg/m2, the true-positive rate in women with an estimated 5-year risk of 3% or higher increased from 10.0% (v2) to 19.8% (v3) and the improvement was greater among women with a BMI of >= 35 kg/m2 (7.6%-19.8%).CONCLUSIONThe BCSC v3 model updates an already well-calibrated and validated breast cancer risk assessment tool to include additional important risk factors. The inclusion of BMI was associated with the largest improvement in estimated risk for individual women. Adding BMI and extended family history to the BCSC model improved discrimination and the true positive rate.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Validation of the breast cancer surveillance consortium model of breast cancer risk
    Jeffrey A. Tice
    Michael C. S. Bissell
    Diana L. Miglioretti
    Charlotte C. Gard
    Garth H. Rauscher
    Firas M. Dabbous
    Karla Kerlikowske
    [J]. Breast Cancer Research and Treatment, 2019, 175 : 519 - 523
  • [2] Validation of the breast cancer surveillance consortium model of breast cancer risk
    Tice, Jeffrey A.
    Bissell, Michael C. S.
    Miglioretti, Diana L.
    Gard, Charlotte C.
    Rauscher, Garth H.
    Dabbous, Firas M.
    Kerlikowske, Karla
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (02) : 519 - 523
  • [3] The Breast Cancer Surveillance Consortium Model Accurately Predicts Invasive Breast Cancer Risk Among Women with LCIS
    Eroglu, I.
    Sevilimedu, V.
    King, T.
    Pilewskie, M.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S65 - S65
  • [4] The contribution of common breast cancer susceptibility loci to the breast density and breast cancer association and the Breast Cancer Surveillance Consortium (BCSC) risk model
    Vachon, Celine M.
    Pankratz, V. Shane
    Scott, Christopher G.
    Haeberle, Lothar
    Ziv, Elad
    Jensen, Matthew R.
    Brandt, Kathleen R.
    Whaley, Dana H.
    Olson, Janet E.
    Heusinger, Katharina
    Hack, Carolin C.
    Jud, Sebastian M.
    Beckmann, Matthias W.
    Tice, Jeffrey A.
    Purrington, Kristen S.
    Sellers, Thomas A.
    Kerlikowske, Karla
    Fasching, Peter A.
    Couch, Fergus J.
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [6] Overview of the breast cancer surveillance consortium.
    Ballard-Barbash, R
    Barlow, WE
    Buist, DS
    Carney, P
    Cutter, G
    Dignan, M
    Geller, B
    Kerlikowske, K
    Miglioretti, D
    Rosenberg, R
    Taplin, S
    Yabroff, R
    Yankaskas, B
    Weaver, D
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2004, 13 (11) : 1866S - 1867S
  • [7] Accuracy of the Breast Cancer Surveillance Consortium Model Among Women with LCIS
    Eroglu, Idil
    Sevilimedu, Varadan
    Park, Anna
    King, Tari A.
    Pilewskie, Melissa L.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2022, 194 (02) : 257 - 264
  • [8] Accuracy of the Breast Cancer Surveillance Consortium Model Among Women with LCIS
    Idil Eroglu
    Varadan Sevilimedu
    Anna Park
    Tari A. King
    Melissa L. Pilewskie
    [J]. Breast Cancer Research and Treatment, 2022, 194 : 257 - 264
  • [9] Advanced Breast Cancer Definitions by Staging System Examined in the Breast Cancer Surveillance Consortium
    Kerlikowske, Karla
    Bissell, Michael C. S.
    Sprague, Brian L.
    Buist, Diana S. M.
    Henderson, Louise M.
    Lee, Janie M.
    Miglioretti, Diana L.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (07) : 909 - 916
  • [10] Relationship Between Mammographic Density and Breast Cancer Death in the Breast Cancer Surveillance Consortium
    Gierach, Gretchen L.
    Ichikawa, Laura
    Kerlikowske, Karla
    Brinton, Louise A.
    Farhat, Ghada N.
    Vacek, Pamela M.
    Weaver, Donald L.
    Schairer, Catherine
    Taplin, Stephen H.
    Sherman, Mark E.
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (16) : 1218 - 1227